NRX Pharmaceuticals Form 25: Nasdaq delists Warrant class
NRX Pharmaceuticals, Inc. is the subject of a Form 25 notification filed by Nasdaq Stock Market LLC to remove a class of Warrant securities from listing and/or registration under Section 12(b) of the Exchange Act.
Rhea-AI Filing Summary
NRX Pharmaceuticals, Inc. is the subject of a Form 25 notification filed by Nasdaq Stock Market LLC to remove a class of Warrant securities from listing and/or registration under Section 12(b) of the Exchange Act. The notice cites compliance with 17 CFR 240.12d2-2 and shows Commission File Number 001-38302. The document includes an expiration reference of March 31, 2018 and lists the issuer's principal office at 1201 Orange Street, Suite 600, Wilmington, DE 19801.
Positive
- None.
Negative
- None.
Key Figures
Commission File Number: 001-38302
CFR citation: 17 CFR 240.12d2-2
Expiry reference: March 31, 2018
+4 more
7 metrics
Commission File Number
001-38302
Form 25 notification
CFR citation
17 CFR 240.12d2-2
Exchange compliance cited in removal notice
Expiry reference
March 31, 2018
Expires field shown in header
Exchange
Nasdaq Stock Market LLC
Exchange filing the Form 25
Security class
Warrant
Described class of securities being removed
Issuer address
1201 Orange Street, Suite 600, Wilmington, DE 19801
Issuer principal executive office
Telephone
(484) 254-6134
Issuer contact number listed
Key Terms
Form 25, 17 CFR 240.12d2-2, withdraw registration, Warrant
4 terms
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(a)(1)"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.
withdraw registration regulatory
"voluntary withdrawal of the class of securities from listing and registration"
Warrant financial
"Warrant (Description of class of securities)"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does NRXP's Form 25 filing mean for NRX Pharmaceuticals (NRXP)?
It notifies the removal of a class of Warrant securities from Nasdaq listing/registration. The filing cites 17 CFR 240.12d2-2 and is submitted under Commission File Number 001-38302, indicating exchange-initiated and issuer-compliant procedures.
Which exchange filed the Form 25 for NRX Pharmaceuticals (NRXP)?
The filing was made by Nasdaq Stock Market LLC. The notice states Nasdaq has complied with its rules under 17 CFR 240.12d2-2 and that the issuer complied with withdrawal requirements for the listed Warrant class.
What specific securities are being removed in the NRXP Form 25?
The filing identifies the affected class as Warrant securities. The notice describes removal/withdrawal of that class from listing and/or registration under Section 12(b) of the Exchange Act.
What issuer contact details appear on the Form 25 for NRX Pharmaceuticals?
The issuer address shown is 1201 Orange Street, Suite 600, Wilmington, DE 19801 and the telephone number listed is (484) 254-6134. The filing also references an expiration of March 31, 2018.
AI-generated analysis. How Rhea-AI works. Not financial advice.
